글로벌 연구동향
핵의학
- 2017년 10월호
[Nucl Med Biol.] Neutron-activatable radionuclide cancer therapy using graphene oxide nanoplatelets.University of North Carolina / 김정현, Michael Jay*
- 출처
- Nucl Med Biol.
- 등재일
- 2017 Sep
- 저널이슈번호
- 52:42-48. doi: 10.1016/j.nucmedbio.2017.05.009. Epub 2017 Jun 1.
- 내용
Abstract
Neutron-activation is a promising method of generating radiotherapeutics with minimal handling of radioactive materials. Graphene oxide nanoplatelets (GONs) were examined as a carrier for neutron-activatable holmium with the purpose of exploiting inherent characteristics for theranostic application. GONs were hypothesized to be an ideal candidate for this application owing to their desirable characteristics such as a rigid structure, high metal loading capacity, low density, heat resistance, and the ability to withstand harsh environments associated with the neutron-activation process. Non-covalently PEGylated GONs (GONs-PEG) offered enhanced dispersibility and biocompatibility, and also exhibited increased holmium loading capacity nearly two-fold greater than GONs. Holmium leaching was investigated over a wide pH range, including conditions that mimic the tumor microenvironment, following neutron irradiation. The in vitro cell-based cytotoxicity analysis of GONs-based formulations with non-radioactive holmium confirmed their safety profile within cells. The results demonstrate the potential of GONs as a carrier of neutron-activatable radiotherapeutic agents.
Author information
Kim J1, Jay M2.
1 Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
2 Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: mjay@unc.edu.
- 키워드
- Graphene oxide; Holmium; Neutron-activation; Radionuclide cancer therapy
- 덧글달기